Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock

Lunai Bioworks Inc.

Acquired CNS patent portfolio via merger; issued $20M Series B Preferred Stock (no cash) to Oncotelic (62.5%) and Pelerin (37.5%).
Series B convertible at $1.50/share into up to 13.33M common shares; conversion requires stockholder approval under Nasdaq Rule 5635.
Patents cover Alzheimer's heterocyclic compounds, anti-TGF-beta agents, apomorphine, and intranasal delivery for CNS disorders.
Closed merger to address Nasdaq stockholders' equity deficiency; also needs bid price compliance by June 4, 2026; Panel decision pending.
Special meeting May 8 includes reverse split proposal for bid price compliance; conversion approval not on that ballot.

item 1.01 item 2.01 item 9.01 item 3.01 item 3.02 item 3.03 item 5.03

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lunai Bioworks Inc. issued preferred stock for $20,000,000.

Security: preferred stock
Consideration: $20,000,000

Exact text from the filing

of the Company, the holders of the Series B Preferred Stock are entitled to a senior liquidation preference equal to the aggregate Stated Value of the Series B Preferred Stock ($20,000,000), and to the extent that, upon receipt of the Stockholder Approval, the Series B Preferred Stock will become convertible into shares of common stock at a fixed Conversion Price

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 20, 2026, the Company received notice from the Panel (in the “Decision”) that it had until April 27, 2026, to regain compliance with the $2.5 million equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “S

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lunai Bioworks Inc. completed an acquisition involving Neurobridge IP Holdings Incorporated for $20,000,000 aggregate stated value of Series B Convertible Preferred Stock (closed 2026-05-01).

Action: acquisition
Counterparty: Neurobridge IP Holdings Incorporated
Consideration: $20,000,000 aggregate stated value of Series B Convertible Preferred Stock
Closing: 2026-05-01

Exact text from the filing

nto an Agreement and Plan of Merger (the “Merger Agreement”) with Neurobridge IP Holdings Incorporated, a Delaware corporation (“Holdings”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lunai Bioworks Inc. entered into Merger Agreement (effective 2026-05-01).

Action: entry
Agreement: merger
Effective: 2026-05-01

Exact text from the filing

The foregoing description of the Merger Agreement is a summary only and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current

View on SEC.gov

Browse all equity issuances →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-26-000653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.